Thymogen (Khavinson) · Glutamyl-Tryptophan
Thymogen (glutamyl-tryptophan, or EW dipeptide) is a synthetic bioregulatory peptide developed by Professor Vladimir Khavinson at the St. Petersburg Institute of Bioregulation and Gerontology in Russia. It is a short-chain dipeptide consisting of L-glutamic acid and L-tryptophan, designed to mimic the immunomodulatory activity of thymic peptides.
Starting dose. 100 mcg — Daily
SubQ injection, any time of day. 10-20 day courses, 2-3 cycles per year with 4-6 months between courses (Khavinson protocol). Pin alone or with other bioregulators only.
Start here. Every protocol below is ordered lowest-first. Begin at the smallest effective dose, hold about a week to assess tolerance, and step up only if needed.
Proposed to act as a gene-regulatory peptide that interacts with DNA sequences in immune cells, modulating expression of genes involved in T-cell differentiation, maturation, and cytokine production.
May enhance thymic output of naive T-cells and restore the balance between T-helper and T-suppressor cell populations, improving overall immune surveillance.
The tryptophan component may influence serotonin and melatonin pathways, though the primary mechanism is believed to be direct peptide-DNA interaction at the epigenetic level according to Khavinson's bioregulation theory.
Days 1-7: Subtle or no noticeable effects. The peptide is thought to initiate gene-regulatory changes in immune cells during this period.
Each reference below was re-fetched from its PubMed record, and the quoted sentence was confirmed to appear in that abstract and to support the claim it sits under. Follow any of them to read the source.
Exact-molecule evidence boundary: the live abstract reports the quoted finding for Thymogen; no broader inference is made.
Immunomodulatory molecule L-Glu-L-Trp was isolated from natural calf thymic peptide complex Thymalin by reverse-phase high performance liquid chromatography.
Evidence scope. Exact molecule wording appears in the quoted live sentence. Only the population/model, formulation, route, and outcome expressly stated there are supported.
Claims we could not support
No abstract we checked supports these for this molecule at this route. That is not the same as saying they are false — it marks where the evidence is missing.
Dose/route: 100 mcg daily; Subcutaneous (SubQ); 10 day course. No selected live abstract sentence verified this complete regimen.
Mechanism as written in source JSON. No selected live abstract sentence verified the complete mechanism at the card formulation/route and relevant population/model.
Primary safety claim as written in source JSON. No selected live abstract sentence verified the complete safety claim for this exact formulation and route.
Two different questions: what is documented about running these together, and what is documented about drawing them into the same syringe. A good pharmacological partner can still have to be pinned separately.
Check any specific pair in the Stack & Interaction Checker, which answers both questions separately. Absence of a documented conflict is not evidence of safety.
Minutes (tiny peptide)
SubQ
SubQ (estimated for small peptide)
Weeks to months (epigenetic gene expression changes persist beyond dosing course per Khavinson theory)
Rapid enzymatic degradation (dipeptidases and aminopeptidases)
Storage. Store refrigerated at 2-8C. Reconstituted solution should be used within 14-28 days.
Approved pharmaceutical in Russia for immune modulation. Not FDA-approved. Classified as a research compound in the US and EU.
Put it to work
Open Thymogen straight into OnePin with your vial and dose pre-filled, then let it handle the syringe math and remind you before the vial runs out.
Open Thymogen in the app →Go deeper
The complete Thymogen walkthrough, real protocol discussion and coaching live inside the BlessUp community on Skool.
Join the community ↗Track it in OnePin. Log vials, draws, and protocols in the app.
Type a name, brand, or tool. Esc closes.